Busulfan/Melphalan Regimen

Known as: BuMel, BuMel Regimen, Busulfan-Melphalan Regimen 
A chemotherapeutic regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
01220052018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
High-risk neuroblastoma is characterized by poor long-term survival, especially for very high-risk (VHR) patients (poor response… (More)
Is this relevant?
Review
2017
Review
2017
High-dose chemotherapy (HDC) followed by reinfusion of cryopreserved autologous PBSC or, less frequently, bone marrowderived stem… (More)
  • table 1
  • figure 1
Is this relevant?
2016
2016
BACKGROUND High-dose chemotherapy with autologous stem cell rescue (ASCR) is a key component of high-risk neuroblastoma therapy… (More)
Is this relevant?
2014
2014
I n this issue of Pediatric Blood & Cancer, Valteau-Couanet et al. [1] update the results of the NB97SFOP protocol activated in… (More)
Is this relevant?
2013
2013
Hepatic injury is a frequent complication of hematopoietic SCT and carries a high risk for early morbidity and mortality. Early… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2013
Review
2013
BACKGROUND (131) I-metaiodobenzylguanidine (MIBG) produces a 37% response rate in relapsed/refractory neuroblastoma, and could be… (More)
Is this relevant?
2008
2008
BACKGROUND An intravenous form of busulfan has been developed to replace oral busulfan in conditioning treatment prior to… (More)
Is this relevant?
2006
2006
7612 Background: Auto-SCT is the preferred treatment modality for MM. From the results of IFM 9502 (Moreau et al. Blood, 2002… (More)
Is this relevant?
Review
2005
Review
2005
therapeutic benefit and toxicity of two MGT regimens (CEM and BuMel) through randomisation [R1] and attempts to eradicate minimal… (More)
Is this relevant?